跳至主要内容
临床试验/NCT06960707
NCT06960707招募中3 期

Prospective Randomized Trial of Two Versus One Week Accelerated Radiotherapy (PRATO)

Weill Medical College of Cornell University6 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2025年4月29日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
招募中
入组人数
400
试验地点
6
主要终点
Rate of RT-related acute toxicity

研究概览

简要总结

This study is comparing two different radiation therapy approaches for early breast cancer to see which one is better for patients. One group will receive radiation over one week (based on the FAST-FORWARD trial), and the other group will receive radiation over two weeks with an extra focused dose (called a "concomitant boost"). The study will look at how the treatments affect side effects, breast appearance, and cancer control in the breast. It also aims to find out if the two-week treatment does a better job at preventing cancer from coming back in the breast over the long term.

详细描述

Radiotherapy: one week (Arm 1) 2600 cGy in 5 fractions whole breast radiotherapy over one week versus 2 weeks (Arm 2), 3200 cGy in 10 fractions with a concomitant tumor bed boost to 3600 cGy. In Arm 2, if no cavity is visible due to oncoplastic surgery, we will deliver 32 Gy to the whole breast only, without a boost.

Hypothesis

A regimen of whole breast radiotherapy to 2600 in five fractions, the current UK standard for early breast cancer (Arm 2), is not inferior to 3200cGy with a concomitant tumor bed boost to 3600 cGy in 10 fractions (Arm 1), in terms of acute toxicity and long-term fibrosis, breast cosmesis and local control at 2 and 5 years. It will also test the hypothesis of superior local control at 10 years in Arm 2 compared to Arm 1.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
Female
接受健康志愿者
否

入选标准

  • •Women status post segmental mastectomy.
  • •If unilateral, pT1-2 breast cancer excised with negative margins.
  • •If bilateral, pT1-2 breast cancer excised with negative margins AND/OR pTis excised with negative margins.
  • •Clinically N0 (cN0 as determined by ultrasound/SOUND criteria) or pN0-1 or Nx or sentinel node negative.
  • •Ductal carcinoma in situ DCIS with negative margins (no DCIS on inked margins).
  • •Women with previous contralateral treated breast cancer can be enrolled in the trial.

排除标准

  • •Previous radiation therapy to the ipsilateral breast.
  • •>90 days from last surgery, unless s/p adjuvant chemotherapy.
  • •>60 days from last chemotherapy.
  • •Male breast cancer.
  • •Ongoing treatment for severe autoimmune disease.

研究组 & 干预措施

ARM 1-2600 cGy in 5 fractions whole breast radiotherapy

Experimental

Patients randomized to ARM 1 will receive 2600 cGy in 5 fractions whole breast radiotherapy over one week

干预措施: Radiation therapy - 1 week (Radiation)

ARM 2- 3200 cGy in 10 fractions with a concomitant tumor bed boost to 3600 cGy

Experimental

Patients randomized to ARM 2 will receive 3200 cGy in 10 fractions with a concomitant tumor bed boost to 3600 cGy.

干预措施: Radiation therapy - 2 weeks (Radiation)

结局指标

主要结局

Rate of RT-related acute toxicity

时间窗: 1 month

The rate of RT-related acute toxicity is defined as cumulative acute toxicity events from the start of radiation treatment to 1 month follow up post RT. The toxicities will be graded by the research nurses assigned to the study according to Common Terminology Criteria for Adverse Events, version 5.0.

次要结局

  • The long-term evaluations at 2 years of fibrosis based on LENT/SOMA(24 months)
  • The long-term evaluations at 2 years of breast cosmesis(24 months)
  • The long-term evaluations at 2 years of local control(24 months)
  • The long-term evaluations at 5 years OF fibrosis based on LENT/SOMA(60 months)
  • The long-term evaluations at 5 years of breast cosmesis(60 months)
  • The long-term evaluations at 5 years of local control.(60 months)
  • Superior local control at 10 years(120 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验